6.5 Takeover Statutes. The Parties will use their respective reasonable best efforts (a) to take all action necessary so
that no Takeover Statute is or becomes applicable to the Merger or any of the other Transactions and (b) if any such Takeover
Statute is or becomes applicable to any of the foregoing, to take all action necessary so that the Merger and the other Transactions
may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to eliminate or minimize
the effect of such Takeover Statute on the Merger and the other Transactions.
6.6 Obligations of Merger Sub. BioTime will take all action necessary to cause each of Merger Sub and the Surviving Corporation
to perform their respective obligations under this Agreement before and after the Effective Time and to consummate the Transactions,
including the Merger, upon the terms and subject to the conditions set forth in this Agreement.
6.7 Employee Benefits. If requested by BioTime at least five (5) business days prior to the Closing, then effective as
of no later than the day immediately preceding the Closing, Asterias will terminate each Asterias Plan intended to be “qualified”
within the meaning of Section 401(a) of the Code.
6.8 Rule 16b-3. Prior to the Effective Time, BioTime and Asterias shall take all such steps as may be required to cause
any acquisitions or dispositions of Asterias Common Stock (including derivative securities with respect to Asterias Common Stock)
or acquisitions of BioTime Common Shares (including derivative securities with respect to BioTime Common Shares) resulting from
the Transactions by each individual who is subject to the reporting requirements of Section 16(a) of the Exchange Act with respect
to Asterias or will become subject to such reporting requirements with respect to BioTime, to be exempt under Rule 16b-3 promulgated
under the Exchange Act, to the extent permitted by applicable Law.
6.9 Security Holder Litigation. Each Party will provide the other Party prompt notice of any litigation brought by any
stockholder of that Party against such Party, any of its Subsidiaries and/or any of their respective directors relating to the
Merger, this Agreement or any of the Transactions, and will provide the other Party with updates and such information as such
other Party will reasonably request with respect to the status of the litigation and discussions between the parties to such litigation
(unless the provision of such updates and information could reasonably be expected to result in a loss of attorney-client privilege).
Asterias will give BioTime the opportunity to participate in the defense of and settlement discussions with respect to any such
litigation and will not settle or make any payment or settlement offer with respect to any such litigation unless BioTime has
consented in writing to such payment or settlement, which consent will not be unreasonably withheld, conditioned or delayed. In
the event of, and to the extent of, any conflict or overlap between the provisions of this Section 6.9 and Section 5.1
or Section 5.2, the provisions of this Section 6.9 will control.
6.10 Delisting. Each of the Parties agrees to cooperate with the other Parties in taking, or causing to be taken, all actions
necessary to delist Asterias Common Stock from NYSE American and terminate its registration under the Exchange Act, provided
that such delisting and termination will not be effective until after the Effective Time.
6.11 Stock Exchange Listing. BioTime will use its reasonable best efforts to cause the BioTime Common Shares to be issued
in the Merger to be approved for listing on NYSE American, subject to official notice of issuance, prior to the Effective Time.
6.12 Accounting Matters. Prior to the Closing Date, each of Asterias and BioTime shall cooperate in good faith with, and
to use commercially reasonable efforts to cause their respective Representatives to cooperate in good faith with, the other Party
and its Representatives in planning for the integration of their respective accounting principles and practices to be used for
the consolidated financial statements of BioTime after the Closing.